CNS Pharmaceuticals (CNSP) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Special Meeting scheduled for November 26, 2024, to vote on three key proposals.
Proposals include a reverse stock split, warrant repricing, and potential adjournment to solicit more proxies.
Board recommends voting in favor of all proposals to maintain NASDAQ listing and improve capital structure.
Voting matters and shareholder proposals
Proposal 1: Authorize Board to effect a reverse stock split at a ratio between 1-for-2 and 1-for-50 within one year.
Proposal 2: Approve repricing of 2,434,120 investor warrants to the lower of $1.13 or the closing price on approval date.
Proposal 3: Authorize adjournment of the meeting to solicit additional proxies if needed.
Each proposal requires more votes cast in favor than against; abstentions and broker non-votes have no effect.
Board of directors and corporate governance
Board and executive officers collectively own less than 1% of outstanding shares.
No individual or group owns more than 5% of shares.
Board has discretion to implement or delay the reverse stock split even if approved.
Latest events from CNS Pharmaceuticals
- TPI 287 was in-licensed, showing strong GBM efficacy and will enter pivotal trials in 2025.CNSP
Investor Update2 Feb 2026 - Pivotal brain cancer trial nears data, with new pipeline asset and strong financial footing.CNSP
Virtual Investor CEO Connect23 Jan 2026 - Pivotal Berubicin data expected H1 2025; TPI-287 to enter glioblastoma trials in 2025.CNSP
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Pivotal Berubicin trial in glioblastoma fully enrolled; top-line data expected Q1 2025.CNSP
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - Berubicin’s pivotal GBM trial is fully enrolled, with data expected in early 2025.CNSP
Investor Update11 Jan 2026 - Key votes include director elections, share authorization increase, and equity plan amendments.CNSP
Proxy Filing2 Dec 2025 - Key votes on reverse stock split and warrant repricing aim to preserve Nasdaq listing and capital access.CNSP
Proxy Filing2 Dec 2025 - Proxy covers board elections, auditor ratification, compensation, and major share increase.CNSP
Proxy Filing2 Dec 2025 - Shareholders to vote on a reverse stock split to maintain NASDAQ compliance; cash for fractional shares.CNSP
Proxy Filing2 Dec 2025